![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: EMP3 |
Gene summary for EMP3 |
![]() |
Gene information | Species | Human | Gene symbol | EMP3 | Gene ID | 2014 |
Gene name | epithelial membrane protein 3 | |
Gene Alias | YMP | |
Cytomap | 19q13.33 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | A0A024QZF8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2014 | EMP3 | PTC04 | Human | Thyroid | PTC | 9.81e-24 | 1.34e+00 | 0.1927 |
2014 | EMP3 | PTC05 | Human | Thyroid | PTC | 6.47e-27 | 1.37e+00 | 0.2065 |
2014 | EMP3 | PTC06 | Human | Thyroid | PTC | 7.26e-32 | 9.01e-01 | 0.2057 |
2014 | EMP3 | PTC07 | Human | Thyroid | PTC | 4.68e-55 | 1.14e+00 | 0.2044 |
2014 | EMP3 | ATC09 | Human | Thyroid | ATC | 4.20e-36 | 1.54e+00 | 0.2871 |
2014 | EMP3 | ATC11 | Human | Thyroid | ATC | 8.34e-12 | 1.81e+00 | 0.3386 |
2014 | EMP3 | ATC12 | Human | Thyroid | ATC | 3.74e-88 | 2.15e+00 | 0.34 |
2014 | EMP3 | ATC13 | Human | Thyroid | ATC | 1.50e-85 | 2.83e+00 | 0.34 |
2014 | EMP3 | ATC1 | Human | Thyroid | ATC | 9.22e-35 | 1.63e+00 | 0.2878 |
2014 | EMP3 | ATC2 | Human | Thyroid | ATC | 5.31e-32 | 4.04e+00 | 0.34 |
2014 | EMP3 | ATC3 | Human | Thyroid | ATC | 3.57e-31 | 1.91e+00 | 0.338 |
2014 | EMP3 | ATC4 | Human | Thyroid | ATC | 3.90e-106 | 2.52e+00 | 0.34 |
2014 | EMP3 | ATC5 | Human | Thyroid | ATC | 4.39e-96 | 2.98e+00 | 0.34 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa043504 | Endometrium | AEH | TGF-beta signaling pathway | 26/1197 | 108/8465 | 3.82e-03 | 2.18e-02 | 1.59e-02 | 26 |
hsa0435011 | Endometrium | AEH | TGF-beta signaling pathway | 26/1197 | 108/8465 | 3.82e-03 | 2.18e-02 | 1.59e-02 | 26 |
hsa043502 | Endometrium | EEC | TGF-beta signaling pathway | 26/1237 | 108/8465 | 5.95e-03 | 3.12e-02 | 2.33e-02 | 26 |
hsa043503 | Endometrium | EEC | TGF-beta signaling pathway | 26/1237 | 108/8465 | 5.95e-03 | 3.12e-02 | 2.33e-02 | 26 |
hsa043507 | Esophagus | ESCC | TGF-beta signaling pathway | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa0435014 | Esophagus | ESCC | TGF-beta signaling pathway | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa043506 | Oral cavity | OSCC | TGF-beta signaling pathway | 60/3704 | 108/8465 | 8.66e-03 | 1.97e-02 | 1.00e-02 | 60 |
hsa0435013 | Oral cavity | OSCC | TGF-beta signaling pathway | 60/3704 | 108/8465 | 8.66e-03 | 1.97e-02 | 1.00e-02 | 60 |
hsa0435022 | Oral cavity | EOLP | TGF-beta signaling pathway | 29/1218 | 108/8465 | 4.81e-04 | 1.92e-03 | 1.13e-03 | 29 |
hsa0435032 | Oral cavity | EOLP | TGF-beta signaling pathway | 29/1218 | 108/8465 | 4.81e-04 | 1.92e-03 | 1.13e-03 | 29 |
hsa0435041 | Oral cavity | NEOLP | TGF-beta signaling pathway | 28/1112 | 108/8465 | 2.46e-04 | 1.62e-03 | 1.02e-03 | 28 |
hsa0435051 | Oral cavity | NEOLP | TGF-beta signaling pathway | 28/1112 | 108/8465 | 2.46e-04 | 1.62e-03 | 1.02e-03 | 28 |
hsa043505 | Prostate | BPH | TGF-beta signaling pathway | 35/1718 | 108/8465 | 1.98e-03 | 7.92e-03 | 4.90e-03 | 35 |
hsa0435012 | Prostate | BPH | TGF-beta signaling pathway | 35/1718 | 108/8465 | 1.98e-03 | 7.92e-03 | 4.90e-03 | 35 |
hsa0435021 | Prostate | Tumor | TGF-beta signaling pathway | 39/1791 | 108/8465 | 2.33e-04 | 1.35e-03 | 8.39e-04 | 39 |
hsa0435031 | Prostate | Tumor | TGF-beta signaling pathway | 39/1791 | 108/8465 | 2.33e-04 | 1.35e-03 | 8.39e-04 | 39 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EMP3 | SNV | Missense_Mutation | c.46N>G | p.Leu16Val | p.L16V | P54852 | protein_coding | tolerated(0.12) | probably_damaging(0.995) | TCGA-EA-A50E-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
EMP3 | SNV | Missense_Mutation | novel | c.258C>G | p.Phe86Leu | p.F86L | P54852 | protein_coding | tolerated(1) | benign(0) | TCGA-MY-A5BF-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
EMP3 | SNV | Missense_Mutation | c.65N>A | p.Ala22Asp | p.A22D | P54852 | protein_coding | deleterious(0) | possibly_damaging(0.825) | TCGA-AY-4070-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fu | PD | |
EMP3 | SNV | Missense_Mutation | c.476N>C | p.Leu159Pro | p.L159P | P54852 | protein_coding | deleterious(0) | benign(0.044) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
EMP3 | SNV | Missense_Mutation | c.208N>G | p.Met70Val | p.M70V | P54852 | protein_coding | deleterious(0) | benign(0.222) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
EMP3 | SNV | Missense_Mutation | c.46N>A | p.Leu16Ile | p.L16I | P54852 | protein_coding | tolerated(0.18) | probably_damaging(0.995) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
EMP3 | SNV | Missense_Mutation | c.127T>C | p.Cys43Arg | p.C43R | P54852 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
EMP3 | SNV | Missense_Mutation | novel | c.395N>A | p.Gly132Glu | p.G132E | P54852 | protein_coding | tolerated(1) | possibly_damaging(0.506) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
EMP3 | SNV | Missense_Mutation | novel | c.164N>T | p.Ser55Ile | p.S55I | P54852 | protein_coding | tolerated(0.22) | benign(0.003) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
EMP3 | SNV | Missense_Mutation | rs754202309 | c.194N>T | p.Ala65Val | p.A65V | P54852 | protein_coding | deleterious(0.02) | benign(0.282) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |